Shopping Cart

Your shopping cart is currently empty

LSKL TFA (Synonyms: LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA(283609-79-0 TFA)...)

Name: LSKL TFA
Brand: TargetMol
SKU: TP2147
Price: 38 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. TP2147 Copy Product Info

Purity: 99.33%

🥰Excellent

LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.

LSKL TFA

Copy Product Info

🥰Excellent

Catalog No. TP2147

Synonyms LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA(283609-79-0 TFA), H-Leu-Ser-Lys-Leu-NH2 TFA

Cas No. 2828433-17-4

Pack Size	Price	USA Stock	Global Stock
1 mg	$38	-	In Stock
5 mg	$82	-	In Stock
10 mg	$117	-	In Stock
25 mg	$232	-	In Stock
50 mg	$343	-	In Stock
100 mg	$497	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.33%

Appearance:Solid

Color:White

Resource Download

COA HPLC MS

Product Introduction

Bioactivity

Description	LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.
In vitro	LSKL TFA from the latent form of TGF-β is responsible for the interaction with the KTFR sequence from ADAMTS1, leading to TGF-β activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds. [3]
In vivo	Intraperitoneal injection of 1 mg/kg LSKL TFA, into male rats exerted a protective effect against subarachnoid fibrosis, attenuated ventricular enlargement, and effectively inhibited the development of hydrocephalus. [1] Intraperitoneal injection of 30 mg/kg LSKL TFA, was able to successfully inhibit the Smad signaling pathway activated by transforming growth factor-β (TGF-β) after partial hepatectomy. LSKL effectively attenuated the activation of TGF-β-Smad signaling by antagonizing TSP-1 rather than reducing TSP-1 protein expression. [2]
Synonyms	LSKL, Inhibitor of Thrombospondin (TSP-1) (TFA), H-Leu-Ser-Lys-Leu-NH2 TFA(283609-79-0 TFA), H-Leu-Ser-Lys-Leu-NH2 TFA

Chemical Properties

Molecular Weight	572.62
Formula	C₂₃H₄₃F₃N₆O₇
Cas No.	2828433-17-4
Smiles	O=C(O)C(F)(F)F.CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O
Relative Density.	no data available
Sequence	H-Leu-Ser-Lys-Leu-NH2
Sequence Short	LSKL

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 200 mg/mL (349.27 mM), Sonication is recommended.

H2O: 80 mg/mL (139.71 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.73 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

H2O/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.7464 mL	8.7318 mL	17.4636 mL	87.3179 mL
5 mM	0.3493 mL	1.7464 mL	3.4927 mL	17.4636 mL
10 mM	0.1746 mL	0.8732 mL	1.7464 mL	8.7318 mL
20 mM	0.0873 mL	0.4366 mL	0.8732 mL	4.3659 mL
50 mM	0.0349 mL	0.1746 mL	0.3493 mL	1.7464 mL
100 mM	0.0175 mL	0.0873 mL	0.1746 mL	0.8732 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc